Table 2.
Key baseline characteristics in the 8/2014–9/2016 EMPRISE cohort
| Before PS matching | After PS matching | ||||
|---|---|---|---|---|---|
| Sitagliptin (N = 201,839) | Empagliflozin (N = 18,880) | Sitagliptin (N = 16,443) | Empagliflozin (N = 16,443) | ||
| Diabetes medication |
⟶ PS matching |
||||
| # antidiabetic drugs (mean) | 2.2 | 2.3 | 2.2 | 2.2 | |
| Treatment naïve (%) | 13% | 7% | 8% | 8% | |
| CV risk factors | |||||
| Any CVD (%) | 37% | 24% | 25% | 25% | |
| CAD (%) | 26% | 18% | 18% | 18% | |
| Stroke (%) | 10% | 5% | 6% | 6% | |
| PAD (%) | 10% | 5% | 5% | 5% | |
| HF (%) | 11% | 5% | 5% | 5% | |
| Lab results (not used for PS matching) | |||||
| HbA1c (mean) | 8.3 | 8.5 | 8.6 | 8.5 | |
Baseline characteristics confirmed the success of creating balanced study arms in the first interim EMPRISE analysis [16]. Cohorts had equivalent scores for a wide range of factors, including CV risk factors; shown here are scores for some key characteristics of interest. Treatment history was included in the PS score to ensure that treatment position was considered during matching. However, the similar treatment histories and HbA1c scores even prior to PS matching confirm that the active comparator was appropriately chosen as in an equivalent position in the treatment pathway to empagliflozin. CAD coronary artery disease, CV cardiovascular, CVD CV disease, HF heart failure, PAD peripheral artery disease, PS propensity score